Showing 6531-6540 of 8286 results for "".
- Upsher-Smith Introduces Isotretinoin Capsules in UShttps://practicaldermatology.com/news/upsher-smith-introduces-isotretinoin-capsules-in-us/2460960/Isotretinoin capsules AB2-rated to the branded product Absorica® (isotretinoin) are now available in 10mg, 20mg, 30mg, and 40mg strengths from
- Study: Laser Plus Topical Steroids May Improve VLS Symptomshttps://practicaldermatology.com/news/study-laser-plus-topical-steroids-may-improve-vls-symptoms/2460959/Adding fractional CO2 laser treatments to topical steroids may maximize treatment outcomes in refractory vulvar lichen sclerosus (VLS), according to a new study in Lasers in Surgery and
- Study Highlights Skin Cancer Disparities in Hispanic/Latino Patientshttps://practicaldermatology.com/news/study-highlights-skin-cancer-disparities-in-hispaniclatino-patients/2460950/When Hispanic/Latino people are diagnosed with skin cancer, their tumors are 17 percent larger than tumors in non-Hispanic White patients, a new study shows. For the study, researchers analyzed a total of 3,486 Mohs micrographic surgeries of basal cell, squamous cell, and bas
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Experts Highlight Need to Focus on Psoriasis Patients’ Wellbeing in Practicehttps://practicaldermatology.com/news/experts-highlight-need-to-focus-on-psoriasis-patients-wellbeing-in-practice/2460945/In addition to managing the clinical manifestations of psoriasis, clinical practices should implement an overall and holistic assessment of the wellbeing of each patient, says a panel of scientists speaking at a symposium during the European Association of Dermatology and Venereology (EADV) 30th&
- Long-term Extension Study Confirms Benefits of Topical Tapinarof in Psoriasishttps://practicaldermatology.com/news/long-term-extension-study-confirms-benefits-of-topical-tapinarof-in-ad/2460936/Final results from the Phase 3 PSOARING 3 long-term extension study show that Dermavant’s investigational tapinarof 1%, once daily, non-steroidal topical cream for the treatment of plaque psoriasis in adults was well tolerated long term, with a safety
- No Concerning Safety Signals for Timber's Topical Isotretinoin in Congenital Ichthyosishttps://practicaldermatology.com/news/no-concerning-safety-signals-for-timbers-topical-isotretinoin-in-congenital-ichthyosis/2460934/Phase 2a study results demonstrate no concerning safety signals and no evidence of significant systemic exposure to isotretinoin or tretinoin after 12 weeks of treatment with Timber Pharmaceuticals’ topical isotretinoin formulation (TMB-001) in pa
- Garnier Launches New Green Beauty Campaignhttps://practicaldermatology.com/news/garnier-launches-new-green-beauty-campaign/2460931/Garnier is launching a new educational campaign on how to live a greener life with content produced by National Geographic CreativeWorks. The series, which will premiere at Expo 2020 Dubai and roll out worldwide, aims to share expert knowledge and real-world advice on key sustainability
- Castle Creek, Mayo Clinic to Collaborate on Therapies for Rare Genetic Connective Tissue Disordershttps://practicaldermatology.com/news/castle-creek-mayo-clinic-to-collaborate-on-therapies-for-rare-genetic-connective-tissue-disorders/2460930/Castle Creek Biosciences, Inc. is collaborating with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta (OI) and classical Ehlers-Danlos syndrome (EDS). Neither rare genetic connective tissue disord